Condition: IDH1 Mutation · Acute Myeloid Leukemia (AML) · Hematopoietic Stem Cell Transplant (HSCT) · Sponsor: Massachusetts General Hospital
This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
This description comes directly from the study's public registry record.
Amir T Fathi, MD · 617-724-1124 · afathi@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Ohio State University Wexner Medical Center- James Cancer Hospital | Columbus, Ohio, United States | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06707493